FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2747080844> ?p ?o ?g. }

• W2747080844 endingPage "72713" @default.
• W2747080844 startingPage "72700" @default.
• W2747080844 abstract "// Shao-Lian Wang 1 , Wen-Bin Dong 2 , Xiao-Lin Dong 1 , Wen-Min Zhu 1 , Fang-Fang Wang 1 , Fang Han 1 and Xin Yan 1 1 Department of Endocrinology, Jinan Central Hospital, Jinan 250013, P.R. China 2 Pharmaceutical Preparation Section, Jinan Central Hospital, Jinan 250013, P.R. China Correspondence to: Xiao-Lin Dong, email: xiaolind0223@163.com Keywords: type 2 diabetes mellitus, single-drug regimen, effects, randomized controlled trials, network meta-analysis Received: March 29, 2017     Accepted: July 18, 2017     Published: August 16, 2017 ABSTRACT We performed a network meta-analysis to compare the efficacy of 12 single-drug regimens (Glibenclamide, Glimepiride, Pioglitazone, Rosiglitazone, Repaglinide, Metformin, Sitaglitin, Exenatide, Liraglutide, Acarbose, Benfluorex, and Glipizide) in the treatment of type 2 diabetes mellitus (T2DM). Fifteen relevant randomized controlled trials (RCTs) were included; direct and indirect evidence from these studies was combined, and weighted mean difference (WMD) and surface under the cumulative ranking curves (SUCRAs) were examined to evaluate the monotherapies. Liraglutide was more effective than Glimepiride, Pioglitazone, Sitaglitin, Exenatide, and Glipizide at reducing glycated hemoglobin (HbA1c) levels. In contrast, Acarbose was less effective than Glibenclamide, Glimepiride, Pioglitazone, Rosiglitazone, Repaglinide, Metformin, and Liraglutide at decreasing HbA1c levels. Reductions in fasting plasma glucose (FPG) levels were similar after all treatments. Rosiglitazone was less effective than Glibenclamide and Repaglinide at reducing total cholesterol (TC) levels. High density lipoprotein (HDL), low density lipoprotein (LDL), and triglyceride levels did not differ after treatment with any of the monotherapies. HbA1c and FPG SUCRA values were highest for Liraglutide, while HbA1c and FPG values were lowest for Acarbose, and TC and LDL values were lowest for Rosiglitazone. These results suggest that Liraglutide may be most effective, and Acarbose least effective, at reducing blood glucose levels, while Glibenclamide, Repaglinide, and Metformin may be most effective, and Rosiglitazone least effective, at reducing lipoidemia, in T2DM patients." @default.
• W2747080844 created "2017-08-31" @default.
• W2747080844 creator A5006624539 @default.
• W2747080844 creator A5012833964 @default.
• W2747080844 creator A5013635684 @default.
• W2747080844 creator A5017610735 @default.
• W2747080844 creator A5046418414 @default.
• W2747080844 creator A5055407056 @default.
• W2747080844 creator A5073478609 @default.
• W2747080844 date "2017-08-16" @default.
• W2747080844 modified "2023-10-13" @default.
• W2747080844 title "Comparison of twelve single-drug regimens for the treatment of type 2 diabetes mellitus" @default.
• W2747080844 cites W115409225 @default.
• W2747080844 cites W1980453186 @default.
• W2747080844 cites W1983184387 @default.
• W2747080844 cites W1986535499 @default.
• W2747080844 cites W1987621741 @default.
• W2747080844 cites W1989089571 @default.
• W2747080844 cites W1992436810 @default.
• W2747080844 cites W2004074514 @default.
• W2747080844 cites W2007453649 @default.
• W2747080844 cites W2010699829 @default.
• W2747080844 cites W2018918964 @default.
• W2747080844 cites W2019764657 @default.
• W2747080844 cites W2029440825 @default.
• W2747080844 cites W2042518766 @default.
• W2747080844 cites W2050722926 @default.
• W2747080844 cites W2053629542 @default.
• W2747080844 cites W2063073799 @default.
• W2747080844 cites W2068815946 @default.
• W2747080844 cites W2071412208 @default.
• W2747080844 cites W2091808438 @default.
• W2747080844 cites W2092328954 @default.
• W2747080844 cites W2095149904 @default.
• W2747080844 cites W2098459806 @default.
• W2747080844 cites W2098923148 @default.
• W2747080844 cites W2099903872 @default.
• W2747080844 cites W2123744385 @default.
• W2747080844 cites W2125043520 @default.
• W2747080844 cites W2132308332 @default.
• W2747080844 cites W2135903328 @default.
• W2747080844 cites W2143732277 @default.
• W2747080844 cites W2144683691 @default.
• W2747080844 cites W2153281308 @default.
• W2747080844 cites W2160663184 @default.
• W2747080844 cites W2161737636 @default.
• W2747080844 cites W2168431214 @default.
• W2747080844 cites W2277541870 @default.
• W2747080844 cites W2312230170 @default.
• W2747080844 cites W2480612209 @default.
• W2747080844 cites W2516762108 @default.
• W2747080844 cites W2525738751 @default.
• W2747080844 cites W2530853433 @default.
• W2747080844 cites W2533627948 @default.
• W2747080844 cites W2538190591 @default.
• W2747080844 cites W2588681363 @default.
• W2747080844 doi "https://doi.org/10.18632/oncotarget.20282" @default.
• W2747080844 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5641162" @default.
• W2747080844 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29069819" @default.
• W2747080844 hasPublicationYear "2017" @default.
• W2747080844 type Work @default.
• W2747080844 sameAs 2747080844 @default.
• W2747080844 citedByCount "7" @default.
• W2747080844 countsByYear W27470808442020 @default.
• W2747080844 countsByYear W27470808442021 @default.
• W2747080844 countsByYear W27470808442023 @default.
• W2747080844 crossrefType "journal-article" @default.
• W2747080844 hasAuthorship W2747080844A5006624539 @default.
• W2747080844 hasAuthorship W2747080844A5012833964 @default.
• W2747080844 hasAuthorship W2747080844A5013635684 @default.
• W2747080844 hasAuthorship W2747080844A5017610735 @default.
• W2747080844 hasAuthorship W2747080844A5046418414 @default.
• W2747080844 hasAuthorship W2747080844A5055407056 @default.
• W2747080844 hasAuthorship W2747080844A5073478609 @default.
• W2747080844 hasBestOaLocation W27470808441 @default.
• W2747080844 hasConcept C126322002 @default.
• W2747080844 hasConcept C134018914 @default.
• W2747080844 hasConcept C2776307423 @default.
• W2747080844 hasConcept C2777180221 @default.
• W2747080844 hasConcept C2777538456 @default.
• W2747080844 hasConcept C2778110834 @default.
• W2747080844 hasConcept C2778384471 @default.
• W2747080844 hasConcept C2779284873 @default.
• W2747080844 hasConcept C2779463123 @default.
• W2747080844 hasConcept C2779768347 @default.
• W2747080844 hasConcept C2780031085 @default.
• W2747080844 hasConcept C2780152017 @default.
• W2747080844 hasConcept C2780323712 @default.
• W2747080844 hasConcept C2780533449 @default.
• W2747080844 hasConcept C2781281211 @default.
• W2747080844 hasConcept C2781308992 @default.
• W2747080844 hasConcept C2910068830 @default.
• W2747080844 hasConcept C555293320 @default.
• W2747080844 hasConcept C71924100 @default.
• W2747080844 hasConcept C98274493 @default.
• W2747080844 hasConceptScore W2747080844C126322002 @default.
• W2747080844 hasConceptScore W2747080844C134018914 @default.
• W2747080844 hasConceptScore W2747080844C2776307423 @default.

• next